and Nef SF2 Tg mice, T-cell loss was severe despite lower levels of Tg expression, suggesting a higher virulence of these alleles. All Nef alleles except the Nef YU10x JR-CSF Tg mice, respectively, despite high levels of Tg expression. Our data show that important differences in the pathogenicities of various Nef alleles can be scored in Tg mice. Interestingly, our results also revealed that some phenotypes can segregate independently, such as CD4 ؉ T-cell depletion and activation, as well as severe depletion of thymic CD4
؉ T cells and peripheral CD4 ؉ T cells. Therefore, expression of Nef alleles in Tg mice under the CD4C regulatory elements represents a novel assay for measuring their pathogenicity. Because of the very high similarity of this murine AIDS-like disease to human AIDS, this assay may have a predictive value regarding the behavior of Nef in infected humans.
The development of AIDS following infection with human immunodeficiency virus type 1 (HIV-1) varies widely but occurs after a relatively long latency in most adults (median, 8 to 10 years) (8, 27, 63, 77) . In children infected at birth, AIDS develops with a bimodal distribution, after either a very short incubation period (median, 4.1 months) or a longer incubation period (median, 6.1 years) (5, 90, 93) . However, in some individuals, the progression of the disease course is very slow and AIDS develops after a much longer period (Ͼ12 years after infection for adults and Ͼ8 years after neonatal infection for children) (10, 78) . These HIV-1-infected individuals are designated slow progressors or long-term nonprogressors (LTNP) (24) . On the contrary, in other HIV-infected individuals, AIDS develops very quickly. These fast progressors are found in both pediatric (5, 80, 87, 93) and adult (43, 63, 72, 76, 77, 80) cohorts. As for many other viral diseases, it is likely that the severity and time course of AIDS development reflect individual host genetic susceptibility/resistance, virus pathogenicity, or both (26) . The host genes could control levels of virus replication and immune response to HIV-1 as well as the signaling pathways with which the viral proteins may interfere. The best example of such genetic susceptibility is that of the CCR5 gene, coding for one of the major coreceptors for HIV-1 infection (73) . A homologous deletion of 32 bp in CCR5 (⌬32-CCR5), found in ϳ1% of the Caucasian population, confers nearly complete protection against HIV-1 infection in vivo (16, 42, 65, 89) . The most evident case of low viral pathogenicity of HIV-1 in humans was documented in the Sydney Blood Bank Cohort, in which eight HIV-1-infected individuals, all LTNP, were infected with a Nef-defective HIV-1 strain by a single blood donor (15, 58) . Studies of this cohort and of a few other individuals infected with HIV-1 strains with deletions or functional defects in Nef (12, 29, 53, 85, 88) strongly suggested that Nef is a major determinant of pathogenicity in humans.
Work with experimental animal models also confirmed the different pathogenicities of various simian immunodeficiency virus (SIV) nef alleles (23) , as well as the low pathogenicities of nef-deleted SIV strains in macaques (51, 67) and of Nef-mutated HIV-1 strains in SCID-hu mice (2, 48) . Finally, expression of HIV-1 or SIV Nef in transgenic (Tg) mice was shown to have very important pathological consequences (7, 20, 21, 35, 47, 57, 64, 94, 96) .
In vitro comparison of various nef alleles and their effects on viral replication and downregulation of CD4 or major histocompatibility complex class I (MHC-I) molecules has revealed a wide range of potencies (4, 13, 14, 19, 28, 30, 69, 100, 104) . A correlation could be established, although not by all groups (74) , between the extent of Nef-induced CD4 downregulation and viral replication and disease progression (11, 13, 30) , suggesting that differences in Nef function may have a major impact on viral pathogenicity. However, a similar head-to-head in vivo comparison has been reported for only two nef alleles in Tg mice with the same promoter (7) . Moreover, the few available Tg mouse models of HIV-1 expression exhibiting immunity defects following expression of the same Nef NL4-3 allele (35, 96) were constructed with different regulatory elements and expressed Nef in different cell subpopulations, making direct comparison difficult.
In another murine model of AIDS, the CD4C/HIV Tg mice expressing only the Nef protein of the HIV-1 strain NL4-3 develop a severe AIDS-like disease in the absence of virus replication (34, 35, 45) . These mice express Nef in immature CD4
ϩ CD8 ϩ and CD4 ϩ CD8 Ϫ thymocytes, in peripheral CD4 ϩ T cells, and in cells of the macrophage/dendritic-cell (DC) lineage (peritoneal, alveolar and tissue macrophages, Kupffer cells, and DCs) (34, 35, 82) . The disease involves pathological changes of immunity-related structures, such as thymic and lymphoid organ atrophy, expansion of marginal zone, and decreased formation of germinal centers and follicular dendriticcell network (35, 82, 83) . Also, immune functions are significantly impaired: downregulation of CD4 cell surface, preferential loss of CD4 ϩ T cells, increase of B-cell numbers, activation of both CD4 ϩ T cells and B cells, hypergammaglobulinemia, loss of lymph node (LN) DCs, accumulation of CD11c ϩ CD11b high DC population, impaired DC function, and lower levels of helper CD4
ϩ T-cell function have been documented (35, 82, 83, 84, 103) . In addition, these Tg mice show an increased susceptibility to Candida albicans (18) . Finally, kidney (cystic dilatation, focal segmental glomerulosclerosis, and interstitial nephritis), lung (lymphocytic interstitial pneumonitis), and heart (cardiomyocytis and cardiomyolysis) diseases develop (35, 46, 49) . These pathological and functional changes are very similar to those found in humans with AIDS.
The large number of Nef-induced phenotypes which can be observed in these CD4C/HIV Tg mice represents a novel in vivo assay for Nef functions. However, it remained to be established whether Nef from other HIV strains would be equally pathogenic when expressed in Tg mice with the same CD4C regulatory elements. Here, we used this Tg mouse model to compare the pathogenicities of six additional nef alleles derived from different HIV-1-infected individuals with distinct clinical courses.
MATERIALS AND METHODS

Proviral and Nef expression constructs for in vitro assays.
For functional analysis, HIV-1 nef alleles were cloned into the biscistronic pCG expression vector (31) or a proviral HIV-1 NL4-3 construct coexpressing Nef and the enhanced green fluorescent protein (eGFP) via an internal ribosome entry site (IRES). Generation of the pCG vectors and the NL4-3 IRES-eGFP constructs carrying a defective nef reading frame or the NL4-3 nef allele has been previously described (91, 92) . PCR amplification and sequencing of nef genes from three individuals with LTNP infection (032an-93, 039nm-94, and AD-93) was carried out as described previously (11, 52) . The JR-CSF (56) and YU10x (61, 62) HIV-1 DNA clones were obtained from Irvin S.Y. Chen and Yoshio Koyanagi and from Beatrice Hahn and George Shaw, respectively, through the NIH AIDS Research and Reference Reagent Program. The SF2 (60) DNA clone was obtained from Louise Poulin and Jay Levy. All nef alleles were cloned into the bicistronic pCG vector, and the proviral HIV-1 NL4-3 IRES-eGFP construct by using unique XbaI (pCG vector) or HpaI (proviral construct) and MluI (both) restriction sites flanking the nef open reading frame (ORF) essentially as described previously (75, 91, 92) . Sequence analysis confirmed that the recombinant proviral constructs contained the correct nef genes and verified the absence of undesired changes.
Virus stocks and in vitro infectivity. For virus production, 293T cells were transfected by the calcium phosphate method with 10 g of the proviral constructs, and the p24 antigen concentrations were quantified as described previously (11) . Virus infectivity was determined on P4-CCR5 (81) and TZM-bl (17) cells by using the ␤-galactosidase screen from TROPIX as described previously (75) .
Receptor modulation in vitro. Jurkat T cells or HeLa CIITA cells were transfected with the pCG vectors or transduced with HIV-1 proviral constructs both coexpressing Nef and eGFP as described previously (54, 75, 92) . Nef-mediated down-or upregulation of cellular receptors was quantified by flow cytometry, along with the expression of the eGFP reporter molecules as described previously (11, 54, 75, 92) . These include CD4, MHC-I, and CD28 measured in Jurkat T cells, MHC-II, and the invariant chain (Ii) associated with immature MHC-II molecules on HeLa CIITA cells (98) . Briefly, four ranges of green fluorescence representing no GFP and low, medium, and high levels of GFP and, indirectly, Nef expression were defined. For quantitative fluorescence-activated cell sorter (FACS) analysis, the mean channel numbers of red fluorescence obtained for cells transfected with a control construct expressing GFP only were divided by the corresponding numbers obtained for cells coexpressing Nef and GFP to calculate the values for down-or up-modulation, respectively. The same ranges of green fluorescence were used in all calculations.
Generation of Tg mice. The nef fragments were amplified from the corresponding proviral DNA by PCR using primers harboring a 5Ј MluI site and a 3Ј NotI site, respectively, to generate unique sites for convenient cloning as follows: primers 585 (5Ј-ACGCGTATGGGTGGCAAGTGGTCAAAA-3Ј) and 584 (5Ј-GCGGCCGCTTAGTTCTTGTAGTACTCCGG-3Ј) for AD-93; primers 585 and 582 (5Ј-GCGGCCGCTCAGCAGTTCTTGTAGTACTC-3Ј) for both 032an and 039nm; primers 585 and 725 (5Ј-GCGGCCGCTCAGCAGTCCTTGTAGT ACTC-3Ј) for JR-CSF; primers 1009 (5Ј-ACGCGTATGGCTGGATGGCCTA CTGTA-3Ј) and 1010 (5Ј-GCGGCCGCTCGAGGTCATCAGTTCTTG-3Ј) for YU10x; and primers 585 and 583 (5Ј-GCGGCCGCTCAGCAGTCTTTGTAG TACTC-3Ј) for SF2. The threonine residue at position 71 of the HIV-1 Nef protein was mutated to arginine (T71R). This mutation was produced using PCR site-directed mutagenesis on a SacI-BamHI HIV-1 fragment subcloned in the pBS KS vector as described previously (37, 40) , using mutational primer 857 (GTACCTGAGGTCTGACTGGAA) containing C, replacing G, at nucleotide 8998 to produce the Nef NL4-3(T71R) mutant. The identity of each allele and the presence of the T71R mutation were confirmed by sequencing. Each of the MluI-NotI fragments was then incorporated into the CD4C/HIV MutG DNA backbone, thus replacing Nef NL4-3(WT) (the wild type). The CD4C/HIV MutG (designated CD4C/HIV-Nef NL4-3 ) Tg DNA construct has been described previously (35) . This Tg DNA harbors a complete HIV-1 NL4-3 genome in which all the known ORFs, except that of Nef, have been interrupted by mutations. These Tg sequences have the ability to express only the Nef gene. Each linearized transgene was purified and inoculated into 1-day-old (C57BL/6 ϫ C3H)F 2 embryos to generate Tg mice, as described previously (34, 35) . A minimum of two independent founder (F) Tg mice faithfully expressing each transgene were generated. Tg lines were established by breeding as a heterozygote for the transgene on the C3H/HeN background.
Transgene expression. Northern blot analysis, using the whole HIV-1 genome as a probe, was used to assess HIV-1 RNA transgene expression, as previously described (34, 35, 37) . The 32 P-labeled bands were detected with the PhosphorImager screen and scanned with the StormImaging unit (Amersham Biosciences). Semiquantitation of the RNA bands was estimated with the ImageQuant software (Amersham Bioscience). The ratio of HIV-specific 8.8-kb signal to the actin-specific signal was obtained. In addition, transgene RNA expression was estimated by real-time quantitative reverse transcription-PCR (RT-PCR), as described previously (103) . For the RT reaction, total RNA (1 to 2 g) isolated from thymuses was used as a template in a 20-l reaction mixture containing 1 ϫ FIRST-strand buffer, as described by the manufacturer (Invitrogen), with Moloney murine leukemia virus reverse transcriptase and 1 mmol of pd(N) 6 random hexamers/liter. After incubation at 42°C for 1.5 h, the enzyme was inactivated at 99°C for 5 min, and the product was diluted to 40 l for amplification. Four microliters was used for quantitative PCR amplification with a Quantitect probe PCR kit (QIAGEN) with a reaction mixture containing 10 l SYBR green PCR master mix, 1.6 l of each primer, at 10 pmol/l, and 4 l template DNA (cDNA) in 2.8 l RNase-free H 2 O. Quantitative PCR was performed with an MX4000 multiplex quantitative PCR instrument (Stratagene). Amplification was performed with a reaction volume of 20 l for 40 cycles (45 s at 95°C and 45 s at 60°C). The primers used were specific for a 150-bp amplicon of fully spliced HIV-1 transcripts and a 100-bp amplicon of the S16 as internal standard. Primers used were a forward primer (oligo 77) located in exon 1 of the human CD4 gene (CCCCACTGGGCTCCTGGTTGCAGC) and a reverse primer for HIV (strain NL4-3) (CAGTCGCCGCCCCTCGCCTCTT) at nucleotide 743 upstream of the major 5Ј splicing junction, and for mouse S16, forward primer oligo 2432 (AGGAGCGATTTGCTGGTGTGG) and reverse primer oligo 2433 (GCTACCAGGGCCTTTGAGATG). The specificity, sensitivity, and reproducibility of the quantitative PCR assays were verified by using cDNA prepared from the thymuses of CD4C/Nef NL4-3(WT) Tg mice used as a positive control.
Detection of Nef protein was done by Western blot analysis, as described previously (34, 35) , using various Nef antibodies. The rabbit anti-Nef antibody used (1:2,000) was prepared by injection of glutathione S-transferase-Nef fused protein as described previously (40) . The monoclonal anti-Nef AE6 (32), EH1, and 6.2 antibodies were obtained from James Hoxie, Kai Krohn, and Vladimir Ovod, through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID.
Histological analysis. Histological assessment on lymphoid and nonlymphoid organs was carried out essentially as previously described (34, 35) . Semiquantitative assessment of the histological phenotypes was done as previously described (36) . The score 1 was given to diseased kidneys with one to five glomeruli affected in their tubules, 2 was given to kidneys with 10 to 50% surface area affected, 3 was given to kidneys with Ͼ50% surface affected, and 4 was given to kidneys with almost all nephrons affected. The individual scores were added up and divided by total number of mice analyzed to obtain average scores.
Flow cytometry of primary mouse cells. Flow cytometry was performed on a FACScan and FACSCalibur (BD Biosciences, San Jose, CA) using antibodies specific for various cell surface markers (CD4, CD8, T-cell receptor ␣␤, and Thy1.2 for T cells, B220 and Mac-1 for B cells and macrophages, respectively, and CD25, CD44, CD45RB, CD69, and CD62L for T-cell activation) as described previously (35, 103) . Cell Quest software (BD Biosciences) was used for analysis.
Apoptosis analysis. This procedure was performed as described previously (84 ϩ T cells were sorted by gating on the PE-positive population by using the MoFlo cell sorter (Dako, CO).
IVKA. Immunoprecipitation was first performed with rabbit anti-Nef polyclonal antibodies followed by an in vitro kinase assay (IVKA) on the immunoprecipitated pellet. A detailed protocol for this technique has previously been published (102) . [ 35 S]Methionine labeling of proteins from thymocytes was described previously (102) .
Statistics. Statistical analyses (analysis of variance, Sigmastat, and Student's t test) were performed as previously described (84, 103) .
RESULTS
Functional activity of primary HIV-1 nef alleles in vitro.
Eight nef alleles derived from HIV-1-infected individuals were assayed for their abilities to modulate CD4, CD28, CXCR4, MHC-I, MHC-II, and Ii surface expression. The primary AD-93, 032an-93, and 039nm-94 nef alleles were derived from individuals with long-term nonprogressive HIV-1 infection (11, 52) . Four nef genes were obtained from well-characterized molecular clones NL4-3 (1), SF2 (3, 14, 60) , JR-CSF (48, 56) , and YU10x (61, 62, 104) . SF2, JR-CSF, and YU10x HIV-1 strains were derived from AIDS patients. A variant of the NL4-3 Nef containing a substitution (T71R) at amino acid residue 71 in the conserved proline-rich region was also included in the analysis. This was done because this amino acid residue is frequently found in primary HIV-1 isolates (29) and because it has been proposed that this variation in Nef might affect T-cell activation and viral replication (25) , although this could not be confirmed in a subsequent study (86) . Alignment of Nef amino acid sequences showed a high conservation of known functional domains and no obvious inactivating point mutations ( Fig. 1) .
We examined the abilities of the eight nef alleles to modulate CD4, MHC-I, and Ii surface expression. The CD4-and MHC-I-downmodulating activities of Nef are well established (59, 79, 95) , whereas the Ii-modulating activity of Nef has been described more recently and might enable HIV-1 to inhibit functional MHC-II antigen presentation (98) . Cells transduced with the proviral NL4-3 construct containing a defective nef 2B, right panel). Vpu-and Env-mediated CD4 down-modulation to some extent complicated the quantitative analysis of this Nef function in the proviral context, particularly at high levels of viral gene expression (Fig. 2B, left panel) . Therefore, we also investigated CD4 down-modulation in Jurkat cells transiently transfected with bicistronic vectors coexpressing the eight HIV-1 nef alleles and GFP. As expected from the results obtained using the proviral constructs, all nef alleles modulated CD4 surface expression, albeit with differential efficiencies (Fig. 2C) . In both cases, the JR-CSF Nef showed the highest activity and the YU10x and AD-93 Nef proteins the weakest activity (compare Fig. 2B , left panel, and C). At medium levels of GFP (corresponding indirectly to Nef expression), the efficiencies of CD4 down-modulation in Jurkat cells expressing Nef alone or in the context of the HIV-1 provirus correlated very well (R 2 ϭ 0.73; P ϭ 0.007). Finally, we also examined the effects of Nef on CXCR4 and MHC-II surface expression. Both receptors were, however, only marginally down-modulated (up to threefold) by the eight nef alleles investigated (data not shown).
To analyze the abilities of these HIV-1 Nef alleles to enhance virion infectivity, we generated viral particles by transient transfection of 293T cells and infected two indicator cell lines with virus stocks containing normalized quantities of the p24 antigen. All nef alleles enhanced HIV-1 infectivity for TZM-bl cells (Fig. 2D, left panel) . This cell line is susceptible to both wild-type and nef-defective HIV-1 infections although Nef enhances viral infectivity about threefold. In contrast, the effects of Nef were much stronger in P4-CCR5 cells. Viral particles produced in the presence of Nef were about 40-fold more infectious for P4-CCR5 cells (Fig. 2D, right panel) . All HIV-1 Nef alleles enhanced infection of P4-CCR5 cells, but the JR-CSF Nef gene was much less effective than the remaining nef genes analyzed (Fig. 2D, right panel) .
Generation of CD4C/HIV-Nef Tg mice expressing different Nef alleles. The pathogenicities of the Nef alleles studied in vitro were then assayed in vivo in Tg mice. Each of these nef alleles replaced Nef from the NL4-3 strain in the HIV MutG cassette in which all the other known ORFs except that of Nef have been interrupted by mutations (35) . The nef alleles were expressed under the control of the chimeric human CD4 promoter and mouse CD4 enhancer regulatory elements (CD4C) to generate CD4C/HIVNef , and CD4C/ HIV-Nef NL4-3(T71R) Tg mice (Fig. 3) . For all transgenes, at least two independent founder lines faithfully expressing the transgene were established and studied.
Expression of the transgene was first assayed by Northern blot analysis on RNA of different organs from mice of each founder line. This analysis revealed the presence of the three major HIV-1 RNA transcripts, mainly in lymphoid tissues (thymus [ Fig. 4A] , spleen, and LN [data not shown]). Expression was not detected in other organs (heart, brain, liver, testis, and muscle) by this technique (data not shown), although previous work with more-sensitive techniques (18, 34, 38, 49, 82 ; unpublished data) has shown that these CD4C regulatory elements allow expression in tissue macrophages and T cells of almost every organ. This expression faithfully reflects the specificity of the CD4C promoter documented previously (34, 38, 39) . Semiquantitative analysis showed that the levels of RNA expression differed among founder lines, as expected, most likely reflecting distinct integration sites of the transgene. This was confirmed by quantitative real-time RT-PCR on RNA extracted from the thymus of mice with each nef allele (Fig. 4A) (Fig. 4B) . However, the use of different anti-Nef antibodies and the different sequences of each Nef allele precluded a direct comparison of the levels of Nef protein expression between these alleles. Therefore, we relied on Tg RNA expression in the thymus, as detected by Northern blot analysis, for comparison.
Tg mice expressing different Nef alleles, including those from LTNP, undergo CD4
؉ T-cell depletion associated with T-cell activation and apoptosis. We previously reported that Tg mice expressing the Nef NL4-3 allele showed a loss of thymocytes, depletion of peripheral CD4 ϩ T cells, and downregulation of CD4 cell surface molecules (35) . Similarly, all Tg mice expressing various Nef alleles at sufficient levels showed a loss of thymocytes (Table 1) . This was most apparent in Tg lines expressing higher levels of the transgene, as expected. However, the loss of thymocytes was less severe in CD4C/HIV YU10x , CD4C/HIV JR-CSF , and CD4C/HIV 039 nm Tg mice, despite relatively high levels of Nef expression in these lines.
Further analysis was performed by use of a FACS on thymocytes from Tg mice expressing each Nef allele. Consistent with previous data on Nef NL4-3 -expressing Tg mice (34, 35, 103) , depletion of DP CD4 ϩ CD8 ϩ and SP CD4 ϩ CD8 Ϫ thymocytes was observed for all Tg lines expressing higher levels of the transgene, although such decrease was not as pro- (Table 1) . Interestingly, a large loss of DP and SP CD4 ϩ thymocytes was documented even in Tg lines expressing lower levels of Nef SF2 , Nef 032an , and Nef NL4-3(T71R) RNA (Table 1), suggesting a high pathogenicity of these alleles. Intriguingly, in Tg mice expressing Nef 032an or Nef NL4-3(T71R) , the loss of total and DP thymocytes was delayed, and it was not as marked in younger (1.5-to 2-month-old) mice as it was for mice expressing other Nef alleles but became severe as the animals got older (approximately 4 to 6 months old). The loss of thymocytes was accompanied by a downregulation of CD4 cell surface molecule in all Tg mice expressing higher levels of Nef alleles, except those expressing Nef YU10x (Table 1 ). The lack of CD4 downregulation in CD4 ϩ T-cell thymocytes expressing Nef YU10x and the very low depletion of these cells is unlikely to reflect lack of protein expression, since mice of the higher-expressor founder were found to express reasonable protein levels relative to those detected in CD4C/HIVNef NL4-3 Tg mice (Fig. 4B) . Rather, this allele appears to be defective in the CD4 downregulation function both in human Jurkat cells (Fig. 2B ) and in primary mouse cells (Table 1 and Fig. 5A) .
A similar FACS analysis on cells of peripheral lymphoid organs (mesenteric and peripheral LN) showed depletion of peripheral CD4 ϩ T cells in Tg mice expressing higher levels of each of the Nef alleles tested, although the depletion in those expressing Nef
YU10x was more modest ( Table 2 ). The downregulation of cell surface CD4 was also apparent in peripheral CD4
ϩ T cells from all Tg mice expressing the transgene at higher levels, except those expressing Nef YU10x and Nef 032an (Table 2 ; see also the FACS profile of a representative mouse in Fig. 5B ). The lack of downregulation of CD4 in peripheral cells from Nef 032an Tg mice was intriguing. It was unlikely to represent an intrinsic lack of CD4 downregulation potential, since Tg thymocytes expressing this allele showed CD4 downregulation and this nef allele was capable of down-modulating CD4 in vitro (Fig. 2) . It may arise from the lack of sufficient Nef expression, since expression was low in these founders. To test this possibility directly, we measured the levels of HIV-1 Tg RNA expression using quantitative RT-PCR on sorted pe- 6 and the number of DP is (45 Ϯ 5.9) ϫ 10 6 ; for Nef 032an Tg mice, the total number of thymocytes is (13.8 Ϯ 10) ϫ 10 6 and the number of DP is (11 Ϯ 8.9) ϫ 10 6 ; and for Nef T71R Tg mice, the total number of thymocytes is (20.3 Ϯ 9.5) ϫ 10 6 and the number of DP is (17.4 Ϯ 8.3) ϫ 10 6 (six to eight mice in each group). b The absolute cell number was calculated by multiplying the total cell number in each organ by the percentage of each cell subset in this organ. c The mean fluorescences for CD4 were obtained by calculating the ratio of CD4 staining in Tg mouse thymuses relative to that of non-Tg mouse thymuses (100%) done in the same experiment, the same day. Mean values were then calculated with the values for each line. [F101376], and CD4C/HIV-Nef NL4-3(WT) [F27367] ) and from a non-Tg littermate were analyzed the same day by flow cytometry for the expression of CD4 and CD8. The percentage of cells found in the relevant quadrant is indicated on the left of the colon, while the underlined number on the right refers to the mean fluorescence intensity. Note the presence of two subsets of CD4 ϩ T cells (CD4 high and CD4 low ) in pLN cells expressing Nef 039nm and to a lesser extent in those expressing Nef SF2 and Nef JR-CSF . These correspond, respectively, to cells expressing low and high levels of Nef, as previously reported for Tg mice expressing Nef NL4-3(WT) (103) . These data are representative of at least three independent experiments with 4 to 10 mice. (C) Three-color FACS analysis (CD4-allophycocyanin, CD8-fluorescein isothiocyanate, and CD44-PE) was performed on pLN cells from a representative mouse from CD4C/HIV-Nef Tg mice. This analysis showed indeed very low levels of Tg RNA in these mice (50-to 100-fold lower in both founders relative to Nef NL4-3 -expressing cells) (data not shown). Loss of CD8 ϩ T cells both in the thymus and peripheral organs could also be documented at a later stage of the disease in most animals, as previously reported for Nef NL4-3 -expressing Tg mice (34, 35, 103) . The number of B220 ϩ (B cells) and Mac1 ϩ (macrophages) cells were sometimes increased in the spleen of these Tg mice (data not shown). Since CD4 ϩ T cells expressing some of these nef alleles are as depleted as those expressing Nef NL4-3 and since the latter cells were previously reported to exhibit an activated/memorylike phenotype (103), we investigated whether CD4 ϩ T cells expressing some Nef alleles were also activated. Triple staining of peripheral LN cells from Tg mice expressing various nef alleles was performed for CD4, CD8, and CD25, CD44, CD69, CD45RB, or CD62L cell surface markers. This FACS analysis revealed that in Tg lines expressing each nef allele tested, aside from Nef YU10x and Nef NL4-3(T71R) , the percentage of CD4 ϩ T cells expressing CD44 high , CD45RB low , or CD62L low was higher than that for non-Tg mice and that a larger proportion of them expressed CD69 and CD25 ( Fig. 5D ; see data shown for one representative mouse in Fig. 5C ). This activated/memory-like phenotype is similar to that previously reported for CD4 ϩ T cells expressing Nef NL4-3 (103) . It is worth noting that the activated phenotype of Nef 032an -expressing CD4 ϩ T cells developed despite the absence of downregulation of CD4 and the very low levels of Nef expression in these cells.
As shown before, Tg CD4 ϩ T cells expressing Nef NL4-3 exhibit an enhanced apoptotic phenotype (84) * , P Ͻ 0.05; ** , P Ͻ 0.01; *** , P Ͻ 0.001. showed a significantly higher proportion of apoptotic/dead CD4 ϩ T cells (Fig. 5E ). We have recently reported that Nef NL4-3 binds to and activates PAK2 when expressed in various immune cell populations of Tg mice (102) . A similar experiment was performed on Tg thymocytes and macrophages of Tg mice expressing each Nef allele. Anti-Nef immunoprecipitation was followed by IVKA, and the 32 P-labeled substrates, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), were visualized by autoradiography. All the tested Nef alleles except the Nef JR-CSF allele were found capable of binding to and activating a Nef-associated kinase (NAK) (Fig. 6) . Moreover, the 32 P-labeled substrates had migration patterns very similar to those obtained with Nef NL4-3 -expressing cells, strongly suggesting that this NAK is PAK2, as previously documented (102) . The lack of mouse PAK2 activation by Nef JR-CSF confirms previous results in studies of human cells in vitro (28 (Fig. 6B) . Thus, the inability to bind to and/or to activate PAK2 appears to be intrinsic to the JR-CSF Nef allele and may be caused by the presence of leucine at position 201 (equivalent to 191 in Nef NL4-3 ), as shown previously (28) . Therefore, this Nef-dependent PAK2 activation appears to be a conserved function among most different Nef alleles.
These results indicate that most of the tested Nef alleles in Tg mice affect CD4
ϩ T cells in a way similar to that of the Nef NL4-3 allele, which was previously reported (34, 35, 84, 102, 103) . Only the Nef YU10x allele appears to be significantly less pathogenic for Tg CD4
ϩ T cells than all other alleles tested, despite being apparently expressed at levels higher than other Nef alleles.
Nef alleles differ in their abilities to induce AIDS-like lung and kidney organ diseases in Tg mice. Tg mice and their non-Tg littermates from each line of Nef allele were monitored for clinical signs of disease (hypoactivity, ruffled hair, weakness, loss of body weight, and early death). Tg mice from different lines expressing Nef NL4-3 (T71R) , Nef 032an , or Nef 039nm all exhibited a mortality rate close to or higher than that observed for Tg mice expressing Nef NL4-3(WT) , while Tg mice expressing another Nef allele (the Nef SF2 allele) showed minimal mortality (Fig. 7A ). For these Nef SF2 Tg mice, this may be related to the relatively low levels of Nef RNA expression. It is worth noting that the high mortality rate of CD4C/HIVNef NL4-3(T71R) Tg mice occurs despite HIV RNA expression lower than that in CD4C/HIV-Nef NL4-3(WT) Tg mice, suggesting a higher pathogenicity for this variant. For all Tg lines of each Nef allele that exhibited high mortality (032an, 039nm, SF2, and NL4-3 [T71R] Nef alleles), a good correlation between shorter survival and higher level of transgene HIV RNA expression in thymocytes could be observed for founders expressing the same allele. One notable exception was the Tg line F101376 expressing the Nef T71R allele: mice from this line had a shorter life span than did those from the F101374 or F101371 lines despite showing equivalent or lower transgene expression in thymocytes. Since organ disease, in particular, kidney disease, largely responsible for poor survival, segregates independently of T-cell loss (36, 37, 102) (see Table 4 ) and can develop in absence of CD4 ϩ T cells (103) , this suggests that another subset(s) of cells critical for organ disease induction expresses the transgene. In the mouse line F101376, the site of transgene insertion may favor enhanced transcription through the CD4C regulatory elements in this particular cell subset yet to be identified.
Histological evaluation of tissues from Nef 032an , Nef 039nm , 7A ; Table 3). Phenotypes include loss of architecture and atrophy of lymphoid organs, as well as kidney (interstitial nephritis, focal segmental glomerulosclerosis, and microcystic dilatation) and lung (lymphocytic interstitial pneumonitis) diseases ( Fig. 7A ; Table 3 ). These pathological lesions affect various percentages of Tg mice and were of different severities, depending on the individual allele and its level of expression (Fig. 7C) . This was especially evident for Nef SF2 Tg mice, which showed typical lesions despite the low levels of allele expression. Importantly, novel phenotypes not previously documented in Tg mice expressing the Nef NL4-3 allele were not observed in these Tg mice.
Therefore, the pathological changes previously observed in Tg mice expressing the Nef NL4-3 allele were not restricted to this single allele but could also be elicited with other primary Nef alleles. In fact, Tg mice expressing some nef alleles from LTNP (032an and 039nm) or other nef alleles (SF2 and NL4- (Fig. 7B) . Histological examination of their organs showed pathological lesions (loss of architecture and atrophy) in their lymphoid organs (LN and spleen) as severe as those observed in Tg mice expressing the Nef NL4-3 allele but not in all mice (Table 3 and data not shown). However, these Tg mice were free of lung and kidney diseases (YU10x and AD-93) or had only minimal lung and kidney diseases (JR-CSF) ( Fig. 7B and C) , despite the fact that transgene RNA expression in the thymus was comparable to or slightly higher than that of CD4C/HIV-Nef NL4-3 or CD4C/ HIV-Nef 032an Tg mice (Fig. 4A) . A summary of the phenotypes observed in these Tg mice expressing different nef alleles is shown in Table 4 .
DISCUSSION
The HIV-1 Nef NL4-3 allele induces a severe AIDS-like disease in Tg mice when expressed under the control of the CD4C regulatory elements in immature and mature CD4 ϩ T cells and in cells of the macrophage/dendritic lineage (34, 35) . We show here that this property is not unique and restricted to this specific allele but is shared by other Nef alleles tested in the same in vivo assay. It is worth noting that novel phenotypes, absent in Tg mice expressing the Nef NL4-3 alleles, were not observed in Tg mice expressing any of the new nef alleles tested. This strongly suggests that all the phenotypes to be elicited by various nef alleles, when expressed in their natural target cells in Tg mice, have indeed developed in Nef NL4-3 -expressing Tg mice. These pathological changes are quite numerous and in fact cover most of the phenotypes associated with this syndrome (AIDS) in humans or in SIV-infected primates, except for pathologies which are known to be caused by pathogens other than HIV or SIV itself.
However, although the seven new nef alleles tested induced CD4 ϩ T-cell depletion to various degrees, they did not induce identical phenotypes, and important differences could be noted. In particular, our data clearly show that the pathogenic potentials of the alleles differ. For example, despite its robust expression, the Nef YU10x allele induced only a modest loss of thymic and peripheral CD4 ϩ T cells, by comparison with other alleles (NL4-3, 039an, and AD-93 Nef alleles). In contrast, the Nef SF2 and Nef 032an alleles were able to elicit significant loss of thymic and peripheral CD4 ϩ T cells, despite their low expression levels. Nef SF2 harbors at position 71 an arginine which has been shown to significantly enhance viral replication in immature DC/T-cell cocultures and to enhance association with Tcell-signaling molecules (Lck, Vav, and T-cell receptor ) (25) . Our data also suggest that, when levels of Nef expression were taken into account, the mutated Nef NL4-3(T71R) allele was more pathogenic in Tg mice than the parental Nef NL4-3 wild-type allele, especially regarding survival and kidney lesions. However, an arginine at this position is not required for the development of an AIDS-like disease in Tg mice, since the Nef 032an allele is highly pathogenic in Tg mice although it contains a threonine at the position corresponding to amino acid residue 71 in the NL4-3 Nef (Fig. 1) . Thus, the influence of the R-to-T variation in the proline-rich region of Nef on its pathogenicity appears to be context dependent.
Further comparison between the immune phenotypes studied here also provided interesting hints regarding Nef pathogenicity. We indeed found an absence of CD4 downregulation on peripheral CD4 ϩ T cells expressing Nef 032an , most likely reflecting its low expression level in these cells, yet these cells were activated and depleted and showed enhanced apoptosis. The genetic segregation of these major phenotypes (CD4 downregulation versus activation/apoptosis/depletion) strongly suggests that CD4 downregulation itself on peripheral CD4 ϩ T cells is not the cause of their depletion. These results are consistent with our previous observations on some mutants of Nef NL4-3 (D174K and RD35/36AA mutants) impaired in their capacity for downregulating CD4 but still competent at inducing an activated/memory-like phenotype and a modest depletion of CD4 ϩ T cells (36) . Previous studies have shown that some LTNP are infected with HIV-1 variants expressing nef alleles showing a diminished activity in CD4 downregulation (4, 68, 101) . One of the three nef alleles from LTNP studied here (AD-93) also showed a diminished capacity for downregulating human CD4 relative to the that of the NL4-3 allele. We found that in CD4C/HIVNef AD-93 Tg mice, CD4 ϩ T-cell depletion was severe despite only modest CD4 downregulation. Also, the CD4C/HIVNef 032an Tg mice did not exhibit much of a downregulation of murine CD4 on peripheral T cells despite showing a loss of this T-cell population and severe lung and kidney diseases. Thus, effective CD4 down-modulation does not seem sufficient for Nef to cause CD4 ϩ T-cell depletion and severe disease in Tg mice.
A second apparently discordant finding observed with two nef alleles and not previously documented with the Nef allele is the lack of an activated/memory-like phenotype and of detectable enhanced apoptosis of CD4 ϩ T cells expressing Nef NL4-3(T71R) (F101374 and F101376) and Nef YU10x (F92751). However, the Nef NL4-3(T71R) -expressing CD4 ϩ T cells were modestly depleted to levels comparable to the levels of CD4 ϩ T cells expressing other virulent alleles at comparable low levels (Nef 032an ). The genetic segregation of these two phenotypes suggests that the activated state of CD4 ϩ T cells may not be the single major factor responsible for their Nefinduced depletion. The state of activation of the CD4 ϩ T cells is now largely interpreted as a plausible mechanism for the CD4 ϩ T-cell loss observed for HIV-1-infected individuals (22, 33, 41, 71, 97) . Our results with this Nef NL4-3(T71R) allele suggest alternative, yet unknown mechanism(s) of cell death induced by HIV-1 Nef in these Tg mice. We have already excluded Fas, FasL, interleukin-1␤-converting enzyme, and tumor necrosis factor receptor I pathways by showing that depletion of Nef NL4-3 -expressing CD4 ϩ T cells is not abrogated in Tg mice deficient in each of these four genes (84) .
The third interesting discordant finding revealed by our study is that thymic and peripheral CD4 ϩ T cells can be depleted independently following Nef expression. We indeed found that SP CD4 ϩ thymocytes were depleted only mildly in most CD4C/HIV-Nef 039nm Tg mice, while their peripheral CD4 ϩ T cells were severely depleted. Similarly, in CD4C/HIVNef AD-93 Tg mice, peripheral CD4 ϩ T cells appeared more severely depleted than the thymic SP CD4 ϩ T cells. Assuming that Nef expression levels are not downregulated specifically in SP CD4
ϩ thymocytes, these results strongly suggest that Nefmediated depletion of thymic and peripheral CD4 ϩ T cells can occur independently and possibly through distinct pathways and that some Nef alleles (such as the Nef 039nm or Nef allele) may interact more efficiently than others with effectors of peripheral CD4 ϩ T cells than of thymic CD4 ϩ T cells. In independent studies of Tg mice expressing some mutants of Nef NL4-3 (D174K and RD35/36AA mutants), we previously reached similar conclusions (37) . This may partly explain why the thymic function and regenerative capacity may be conserved better and for a longer time in some HIV-1-infected individuals (55, 70, 71) .
The capacity for eliciting another organ phenotype, kidney disease (focal segmental glomerulosclerosis, microcystic dilatation, and tubulointerstitial nephritis), also distinguishes the seven new alleles tested. Three (YU10x, JR-CSF, and AD-93 Nef alleles) of the seven nef alleles were totally or almost completely defective at inducing kidney disease, even though their levels of RNA expression were comparable to or higher than the levels of other Nef alleles causing this disease, including the wild-type Nef NL4-3 previously reported (35) . This suggests that the molecular or cellular requirements for the induction of kidney disease are more stringent than those for the loss of CD4 ϩ T cells, since two of these alleles (the JR-CSF and AD-93 Nef alleles) were able to induce significant CD4 ϩ T-cell loss. A similar phenomenon was observed in studies of some mutants of Nef NL4-3 in Tg mice, in which it was found that mutants had lost their capacity for eliciting kidney disease more easily than their capacity for inducing T-cell changes (37) . More recently, it was reported that Tg mice expressing the whole genome of HIV-1 JR-CSF under the regulation of its own long terminal repeat promoter showed only a modest depletion of peripheral CD4 ϩ T cells but no changes in the thymocyte populations or any organ disease (99) . These results are consistent with the phenotypes observed in our CD4C/ HIV-Nef JR-CSF Tg mice, i.e., a depletion of peripheral CD4 ϩ T cells more severe than that of thymic CD4 ϩ T cells and presence of only minimal organ diseases. The inability of Nef JR-CSF to activate PAK2 may be responsible for some of its milder phenotypes. However, it would have to be hypothesized that such activation is not sufficient or context dependent, since another Nef allele (the YU10x Nef allele) with a similar phenotype is able to activate PAK2.
Interestingly, the three nef alleles from LTNP which were studied in Tg mice were quite pathogenic in this in vivo biological assay, while one allele from an AIDS patient (the YU10x Nef allele) had very low virulence. If this Tg assay is of any relevance for predicting pathogenicity in humans, this suggests that the slow tempo of AIDS development in the LTNP patients from which these nef genes were obtained reflects mutations in viral genes other than nef or is caused by a host genetic resistance in these individuals. It may also suggest that some of the HIV-1 variants molecularly cloned from AIDS patients may not fully represent the virulent HIV-1 population causing the disease. This is known to occur and has been well documented in the macaque model of SIV infection in which reinoculation of viruses is possible (6, 9, 44, 50, 66) . The availability of such an in vivo Tg assay could then help in classifying LTNP patients in distinct subgroups and to assess the virulence of specific HIV-1 variants obtained from them and from individuals with AIDS. Obviously, such comparative analysis should take into account the specificity of the Tg system, i.e., minimal contribution of opportunistic infection, since these mice are kept in specific-pathogen-free conditions, presence of a genetic background susceptible for the development of HIV-1-associated nephropathy, and absence of virus replication.
In conclusion, our data indicate that the CD4C/HIV Tg mouse model system represents a biological in vivo assay for nef alleles. Although this assay does not score the influence of Nef on viral replication, it scores numerous other phenotypes caused by Nef expression in very distinct primary T-cell (immature and mature) and myeloid cell (macrophage/DC) subpopulations. These phenotypes consist of perturbations of immature and mature T cells as well as severe organ diseases similar to those found in human AIDS. We have shown here that very important different T-cell changes may be induced by different Nef alleles. These phenotypes could not have been scored in vitro or easily in HIV-infected humans, highlighting the need to study HIV-1 pathogenesis in primary, unstimulated T cells and the advantage to use an animal model for such an investigation. It remains to be determined whether such assay in the mouse has any predictive value regarding the behavior of Nef in infected humans.
